Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when COCH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsEnvoy Medical expands board to seven, adds former Boston Scientific M&A veteran McKhann
Filed April 21, 2026 · Period ending April 15, 2026 · ~1 min read
Key Changes
-
medium
Charles S. McKhann appointed as Class I director and Compensation Committee member, expanding board from six to seven members effective April 15, 2026.
Item 5.02 verify on EDGAR → -
medium
McKhann led two medical device companies (Silk Road Medical and Apollo Endosurgery) through successful acquisitions by Boston Scientific, bringing M&A and exit experience to the board.
Item 5.02 verify on EDGAR → -
low
New director granted stock options for 100,000 shares at $0.72 exercise price, vesting monthly over 36 months, aligning interests with shareholders.
Item 5.02 verify on EDGAR → -
low
Board determined McKhann meets Nasdaq and SEC independence standards, including enhanced criteria for Compensation Committee service.
Item 5.02 verify on EDGAR →
Summary
Envoy Medical added medical device veteran Charles S. McKhann to its board of directors, expanding the board to seven members. McKhann brings notable M&A experience, having led both Silk Road Medical and Apollo Endosurgery through acquisitions by Boston Scientific between 2021 and 2024.
He currently serves on the board of public diagnostics company Exagen and as Executive Chairman of surgical robotics firm Distalmotion. For retail investors, this appointment signals potential strategic direction. McKhann's track record centers on building medical device companies to successful exits rather than long-term independent growth.
His addition to the Compensation Committee gives him influence over executive incentives. The timing and expertise suggest Envoy may be positioning for strategic alternatives, though no such plans were disclosed. Watch whether Envoy announces strategic reviews, partnership discussions, or changes to executive compensation structures in coming quarters. McKhann's 36-month vesting schedule provides some alignment for longer-term value creation, but his background suggests the board may be exploring exit opportunities for this hearing implant technology company.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Envoy Medical, Inc. (the “Company”), the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company’s 2027 annual meeting of stockholders. In connection with and effective as of his appointment to the Board, Mr. McKhann was also appointed to the Board’s Compensation Committee (the “Compensation Committee”). Also in connection with his appointment, the size of the Board was increased from six members to seven members.
The company expanded its Board of Directors by appointing Charles S. McKhann as a new Class I director with a term through the 2027 annual meeting. McKhann was simultaneously appointed to the Compensation Committee, and the Board size increased from six to seven members. This represents a standard board expansion with an experienced medical device executive.
Added in current filing · verify on EDGAR →
Mr. McKhann currently serves as a director of Exagen, Inc., a publicly traded diagnostics company, and as Executive Chairman at Distalmotion SA, a privately held surgical robotics company. Previously, Mr. McKhann served as the President, Chief Executive Officer, and a member of the board of directors of Silk Road Medical, Inc. (“Silk Road”), a medical device company, from November 2023 to September 2024, when Silk Road was purchased by Boston Scientific Corporation, and served as Chief Executive Officer, President and a member of the Board of Directors of Apollo Endosurgery, Inc. (“Apollo”), a medical device company, from March 2021 to April 4, 2023, when Apollo was purchased by Boston Scientific Corporation.
McKhann brings significant medical device industry experience, having led two companies (Silk Road Medical and Apollo Endosurgery) through successful acquisitions by Boston Scientific. He currently serves on the board of a public diagnostics company and as Executive Chairman of a surgical robotics company, indicating active involvement in the medical technology sector.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
As of the date of his appointment to the Board, Mr. McKhann was awarded stock options to purchase 100,000 shares of the Company’s Class A Common Stock, par value of $0.0001 per share, at a price of $0.72 per share, which stock option award will vest in 36 equally monthly installments.
McKhann received a stock option grant for 100,000 shares at an exercise price of $0.72 per share, vesting monthly over three years. This standard equity compensation aligns the new director's interests with shareholders and represents approximately $72,000 in potential value at the grant price.
Added in current filing · verify on EDGAR →
The Board has determined that Mr. McKhann is an independent director in accordance with the listing requirements of the Nasdaq Capital Market and the standards promulgated by the Securities and Exchange Commission, including enhanced independence criteria applicable to members of the Compensation Committee.
The Board formally determined that McKhann meets independence standards under Nasdaq and SEC rules, including the enhanced independence requirements for Compensation Committee members. This confirms no conflicts of interest or related-party relationships that would compromise his oversight role.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify